Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 176-183 , October 2010

Serum Procalcitonin in Systemic Autoimmune Diseases—Where Are We Now?

  • Irina Buhaescu, MD

      Affiliations

    • Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA
    • Corresponding Author InformationAddress reprint requests to Irina Buhaescu, MD, Boston University School of Medicine, Rheumatology Section, 72 East Concord Street, E-5, Boston, MA 02118
    • ,
  • Robert A. Yood, MD

      Affiliations

    • Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA
    • ,
  • Hassan Izzedine, MD, PhD

      Affiliations

    • Department of Nephrology, Pitie Salpetriere Hospital, Paris, France

References 

  1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS) (A prospective study). J Am Med Assoc. 1995;273:117–123
  2. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol. 2002;72(4):643–649
  3. Nishikura T. Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med. 1999;25:1031
  4. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentration in patients with sepsis and infection. Lancet. 1993;341:515–518
  5. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404
  6. Becker KL, Nylén ES, White JC, Müller B, Snider RH. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4):1512–1525
  7. Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock. 2000;14(1):73–78
  8. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 2002;30(9):2091–2095
  9. Nylen ES, Whang KT, Snider RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26(6):1001–1006
  10. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323(1-2):17–29
  11. Preas HL, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184(3):373–376
  12. Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin—a new indicator of the systemic response to severe infections. Infection. 1997;25:329–334
  13. Gendrel D, Bohuon C. Procalcitonin—a marker of bacterial infection. Infection. 1997;133–134
  14. Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977–983
  15. Nylén ES, Snider RH, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 1996;312(1):12–18
  16. Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med. 2000;28:1828–1832
  17. Marc E, Ménager C, Moulin F, Stos B, Chalumeau M, Guérin S, et al. Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during outbreak. Arch Pediatr. 2002;9:358–364
  18. Rau BM, Kemppainen EA, Gumbs AA, Büchler MW, Wegscheider K, Bassi C, et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg. 2007;245:745–754
  19. Ammori BJ, Becker KL, Kite P, Snider RH, Nylén ES, White JC, et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas. 2003;27(3):239–243
  20. Kylänpää-Bäck ML, Takala A, Kemppainen E, Puolakkainen P, Haapiainen R, Repo H. Procalcitonin strip test in the early detection of severe acute pancreatitis. Br J Surg. 2001;88(2):222–227
  21. Laifer G, Wasner M, Sendi P, Graber P, Gratzl O, Huber P, et al. Dynamics of serum procalcitonin in patients after major neurosurgery. Clin Microbiol Infect. 2005;11(8):679–681
  22. Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 1999;18(10):875–881
  23. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infections: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–217
  24. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996–2003
  25. Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, et al. Serum calcitonin precursors in patients with sepsis and infection. J Clin Endocrinol Metab. 1998;83:3296–3301
  26. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007;7:102
  27. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19
  28. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–607
  29. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitoninto shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177:498–505
  30. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheuma. 1997;40(7):1250–1256
  31. Espinosa-Morales R, Escalante A. Use of procalcitonin as a diagnostic test: comment on the article by Eberhard et al. Arthritis Rheum. 1998;41(3):567–568
  32. Tamaki K, Kogata Y, Sugiyama D, Nakazawa T, Hatachi S, Kageyama G, et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol. 2008;35(1):114–119
  33. Shin KC, Lee YJ, Kang SW, Baek HJ, Lee EB, Kim HA, et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis. 2001;60(10):988–989
  34. Quintana G, Medina YF, Rojas C, Fernandez A, Restrepo JF, Rondon F, et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol. 2008;14(3):138–142
  35. Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998;26(5):274–276
  36. Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol. 1998;25(8):1531–1533
  37. Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004;48(2):199–205
  38. Scirè CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123–128
  39. Schmidt J, Duhaut P, Bourgeois AM, Salle V, Smail A, Chatelain D, et al. Procalcitonin at the onset of giant cell arteritis and polymyalgia rheumatica: the GRACG prospective study. Rheumatology (Oxford). 2009;48(2):158–159
  40. Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?. Ann Rheum Dis. 2003;62(4):337–340
  41. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–607
  42. Morath C, Sis J, Haensch GM, Zeier M, Andrassy K, Schwenger V. Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading. Nephrol Dial Transplant. 2007;22(9):2701–2704
  43. Steinbach G, Bölke E, Grünert A, Störck M, Orth K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004;116(24):849–853
  44. Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2003;15(3):297–301
  45. Nylen ES, O'Neill W, Jordan MH, Snider RH, Moore CF, Lewis M, et al. Serum procalcitonin as an index of inhalation injury in burns. Horm Metab Res. 1992;24(9):439–443
  46. Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35(5):290–295
  47. Martinot M, Sordet C, Soubrier M, Puéchal X, Saraux A, Lioté F, et al. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol. 2005;23(3):303–310
  48. Hügle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, et al. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol. 2008;26(3):453–456
  49. Fottner A, Birkenmaier C, von Schulze Pellengahr C, Wegener B, Jansson V. Can serum procalcitonin help to differentiate between septic and nonseptic arthritis?. Arthroscopy. 2008;24(2):229–233
  50. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin guided antibiotic use vs a standard approach in lower respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000–2008
  51. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177:498–505
  52. Nylen E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003;15(6):823–82436
  53. Schuetz P, Christ-Crain P, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—hope for hype?. Swiss Med Wkly. 2009;139(23-24):318–326
  54. Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection. 2007;35(5):352–355

PII: S0049-0172(09)00146-2

doi: 10.1016/j.semarthrit.2009.10.004

Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 176-183 , October 2010

Article Tools